Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,316 across all filing types
Latest filing 2025-02-06 Regulatory Filings
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
Newspaper Publication
Regulatory Filings
2025-02-06 English
Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Dr. Reddy's Laboratories Ltd. about entering into a license agreement with Shanghai Henlius Biotech, Inc. for commercialization of a biosimilar product. It includes specifics about the agreement terms, payments, and strategic rationale. The document references compliance with SEBI Listing Regulations and provides a press release with extensive details about the collaboration, product, and company background. There are no financial statements, quarterly or annual results, or audit information. The content is focused on a capital/financing update related to a licensing deal and strategic partnership. The document length is over 14,000 characters, indicating it is not a brief announcement but a substantive disclosure. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-02-06 English
6-K Filing
Regulatory Filings
2025-02-06 English
FORM 6-K
Regulatory Filings
2025-02-05 English
Schedule of Analyst / Institutional Investor Meeting
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the schedule of analyst/institutional investor meetings. It is an intimation under SEBI regulations about upcoming investor conferences and does not contain any financial data, report, or detailed presentation. The length is only 1478 characters, which is quite short and fits the profile of a regulatory announcement rather than a full report or presentation. There is no indication of financial results, management discussion, or detailed investor presentation content. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-05 English
FORM 6-K
Regulatory Filings
2025-02-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.